DJIA 18,030.21 0.00 0.00%
NASDAQ 4,773.47 0.00 0.00%
S&P 500 2,081.88 0.00 0.00%
market minute promo


3.00 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $3.00 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.00
Previous Close $3.00
Daily Range $2.92 - $3.03
52-Week Range $2.91 - $9.80
Market Cap $310.5M
P/E Ratio -4.24
Dividend (Yield) $0.00 (0.0%)
Volume 983,482
Average Daily Volume 2,114,788
Current FY EPS -$0.76





VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary Rss Feed

3 Biotech Stocks I Don't Want for Christmas

I’d prefer coal in my stocking to these three troubled biotech stocks.

Novo Nordisk Enters Anti-Obesity Space With New FDA Approval

Contrave Prescriptions Still Rising In A Down Week

Orexigen - Contrave Script Numbers Remain Impressive

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?

New Obesity Drug Available Soon

Orexigen is close to getting Mysimba on the market in Europe.

Arena And Vivus Investors Need To Grasp Implications Of Orexigen

Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

Vivus Tries To Lead Obesity Space With Insurance Coverage

See More VVUS News...

VVUS's Top Competitors

VVUS $3.00 (0.00%)
Current stock: VVUS
JNJ $104.59 (0.00%)
Current stock: JNJ
NVS $93.91 (0.00%)
Current stock: NVS
RHHBY $34.28 (0.00%)
Current stock: RHHBY